In preclinical studies, FXR activation has been shown to attenuate hepatic steatosis, reduce lipotoxicity and inflammation, increase insulin sensitivity, and exhibit direct anti-inflammatory and antifibrotic effects, suggesting that modulation of FXR has beneficial effects on obesity-related liver diseases (207). The gene discussed is INS; the disease is fatty liver disease.